[Neoantigens and Whole-Exome Sequencing].

Area of Science:

• Cancer Immunology
• Immunotherapy
• Genomics

Background:

• Somatic mutations accumulate during cancer progression, leading to the formation of tumor-specific antigens.
• Neoantigens, derived from these mutations, possess higher antigenicity than self-antigens and are recognized by T cells.
• Neoantigens are crucial for eliciting anti-tumor immune responses.

Purpose of the Study:

• To highlight the significance of neoantigens in cancer immunity.
• To outline the process of neoantigen identification and therapeutic development.
• To discuss the progress of neoantigen-targeted cancer immunotherapy.

Main Methods:

• Whole-exome sequencing to detect somatic mutations.
• Computational algorithms to predict MHC-peptide binding affinity for neoantigen identification.
• Immunological assays to confirm neoantigenicity.
• Development of personalized vaccines (peptides, dendritic cells, RNAs) targeting neoantigens.

Main Results:

• Neoantigens are identified as key players in cancer immunity.
• Neoantigen-targeted therapies are under active development.
• Clinical trials for neoantigen-based cancer vaccines are underway.

Conclusions:

• Neoantigens represent ideal targets for effective cancer immunotherapy.
• Personalized neoantigen vaccines are a promising therapeutic strategy.
• Ongoing clinical trials demonstrate the translational potential of neoantigen-targeted therapies.